News & Views | Telix Pharmaceuticals Limited

Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery

Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate cancer.

Completion of Phase I Enrolment of Japanese Renal Cancer Study

Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan.

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey

Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical trial

Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress

Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of live presentations held on 29th October 2020.

Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020

Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased to be sponsoring the “Radiopharmaceuticals drug development: current and future trends” session on Thursday 29th October 2.15 pm – 3.00 pm (AEST).

Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent

Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of glioma

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Telix announces it has entered into a strategic collaboration agreement with Varian Medical Systems

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product